Summary
Coronary heart disease (CHD) is the leading cause of death in women, and the risk of this disease rises markedly after loss of ovarian function. Hormone replacement therapy (HRT) can reduce the incidence of CHD in postmenopausal women by 50%. HRT causes changes in lipids and lipoproteins, but it is now clear that many other effects of gonadal steroid hormones have important influences on the cardiovascular system. These nonlipid effects include a variety of changes in other metabolic risk factors for CHD, as well as direct arterial effects.
Insulin resistance and hyperinsulinaemia may be pivotal disturbances in the pathogenesis of CHD. Estradiol reverses the effects of menopause on glucose and insulin metabolism, resulting in an increase in pancreatic insulin secretion and a decrease in insulin resistance, although other types of estrogen may not do this. Androgenic progestogens may oppose this potentially beneficial effect on insulin resistance.
Central obesity is linked with many CHD risk factors, and HRT reverses the increased fat distribution that results from loss of ovarian function at the menopause. HRT may also improve the balance between coagulation and fibrinolysis, resulting in a reduction in arterial thrombosis.
Finally, estradiol acts directly on the arterial wall, modifying both endothelium-dependent and calcium-dependent processes. These actions result in improved blood flow and reduced blood pressure and, importantly, have the potential to reduce myocardial ischaemia.
Similar content being viewed by others
References
Abbott W, Lillioja S, Young A. Relationships between plasma lipoprotein concentrations and insulin action in an obese hyperinsulinaemic population. Diabetes 36: 897–904, 1987
Bourne T, Hillard TC, Whitehead MI, Crook D, Campbell S. Oestrogens, arterial status, and postmenopausal women. Lancet 335: 1470–1471, 1990
Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 75: 1102–09, 1987
Cagnacci A, Soldani R, Carriero PL, Paoletti AM, Fioretti P, et al. Effects of low doses of transdermal 17β-estradiol on carbohydrate metabolism in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 74: 1396–1400, 1992
Collins P, Rosano GMC, Jiang C, Lindsay D, Sarrel PM, et al. Cardiovascular protection by oestrogen — a calcium antagonist effect? Lancet 341: 1264–65, 1993
Crook D, Cust MP, Gangar KF, Worthington M, Hillard TC, et al. Comparison of transdermal and oral estrogen/progestin hormone replacement therapy: effects on serum lipids and lipoproteins. American Journal of Obstetrics and Gynecology 166: 950–55, 1992
Folsom AR, Wu KK, Davis CE, Conlan MG, Sorlie PD, et al. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 91: 191–205, 1991
Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall Study. British Medical Journal 287: 867–870, 1983
Gangar KF, Vyas S, Whitehead M, Crook D, Meire H, et al. Pulsatility index in internal carotid artery in relation to transdermal oestradiol and time since menopause. Lancet 338: 839–842, 1991
Ginsburg J. The menopause, hormone replacement therapy and the cardiovascular system. In Burger H, Boulet M (Eds) A portrait of the menopause, pp. 45–66, Parthenon, Carnforth, 1991
Godsland IF, Gangar KF, Walton C, Cust MP, Whitehead MI, et al. Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 42: 846–853, 1993
Gordon T, Kannel WB, Hjortland MC, McNamara PM. Menopause and coronary heart disease. The Framingham Study. Annals of Internal Medicine 89: 157–161, 1978
Heinrich J, Sandkamp M, Kokott R, Schulte H, Assmann G. Relationship of lipoprotein (a) to variables of coagulation and fibrinolysis in a healthy population. Clinical Chemistry 37: 1950–1954, 1991
Jarrett RJ, McCartney P, Keen H. The Bedford Survey: ten year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycaemic controls and risk for coronary heart disease in borderline diabetics. Diabetologia 22: 79–84, 1982
Jiang C, Poole-Wilson PA, Sarrel PM, Mochizuki S, Collins P, et al. Effect of 17/β-oestradiol on contraction, Ca2+ current and intracellular free Ca2+ in guinea-pig isolated cardiac myocytes. British Journal of Pharmacology 106: 739–745, 1992b
Jiang C, Sarrel PM, Lindsay DC, Poole-Wilson PA, Collins P. Endo-thelium-independent relaxation of rabbit coronary artery by 17β-oestradiol in vitro. British Journal of Pharmacology 104: 1033–1037, 1991
Jiang C, Sarrel PM, Poole-Wilson PA, Collins P. Acute effect of 170-oestradiol on rabbit coronary artery contractile responses to endothelin-1. American Journal of Physiology 263: H271–H275, 1992a
Juhan-Vague I, Alessi MC, Joly P, et al. Plasma plasminogen activator inhibitor 1 in angina pectoris. Influence of plasma insulin and acute-phase response. Arteriosclerosis 9: 362–367, 1989
Knopp RH. The effects of postmenopausal estrogen therapy on the incidence of arteriosclerotic vascular disease. Obstetrics and Gynecology 72: 23S–30S, 1988
Krauss RM. The tangled web of coronary risk factors. American Journal of Medicine 90: 36S–41S, 1991
Ley CJ, Lees B, Stevenson JC. Sex- and menopause-associated changes in body-fat distribution. American Journal of Clinical Nutrition 55: 950–954, 1992
Ley C, Swan J, Godsland IF, Walton C, Crook D, et al. Insulin resistance, lipoproteins, body fat and hemostasis in non-obese males with angina and normal or abnormal coronary angiograms. Journal of the American College of Cardiologists, in press, 1994
Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, et al. Retardation of angiographic progression of coronary artery disease by nifedipine. Lancet 335: 1109–1113, 1990
Lowe GDO, Greer IA, Cooke TG, et al. Risk of and prophylaxis for venous thromboembolism in hospital patients. British Medical Journal 305: 567–574, 1992
Magness RR, Rosenfeld CR. Local and systemic estradiol-17 beta: effects on uterine and systemic vasodilation. American Journal of Physiology 256: E536–E542, 1989
Manolio TA, Harlan WR. Research on coronary disease in women: political or scientific imperative? British Heart Journal 69: 1, 1993
Notelovitz M, Johnston M, Smith S, Kitchens C. Metabolic and hormonal effects of 25mg and 50mg 17β estradiol implants in surgically menopausal women. Obstetrics and Gynecology 70: 749–754, 1987
Oliver MF, Boyd GS. Effect of bilateral ovariectomy on coronary artery disease and serum lipid levels. Lancet 2: 690–692, 1959
Padwick ML, Whitehead MI, Coffer A, King RJB. Demonstration of estrogen receptor related protein in female tissues. In Studd JWW, Whitehead MI (Eds) The menopause, pp. 227–233, Blackwell, Oxford, 1989
Paganini-Hill A, Ross RK, Henderson BE. Postmenopausal oestrogen treatment and stroke: a prospective study. British Medical Journal 297: 519–522, 1988
Pinto S, Rostagno C, Coppo M, et al. No sign of increased thrombin generation in menopause. Thrombosis Research 58: 645–651, 1990
Proudler AJ, Felton CV, Stevenson JC. Ageing and the response of plasma insulin, glucose and C-peptide concentrations to intravenous glucose in postmenopausal women. Clinical Science 83: 489–94, 1992
Proudler AJ, Godsland IF, Stevenson JC. Insulin propeptides in conditions associated with insulin resistance in humans and their relevance to insulin measurements. Metabolism, in press, 1994
Reaven GM. Role of insulin resistance in human disease. Diabetes 37: 1595–1607, 1988
Rönnemaa T, Laakso M, Pyörälä K, Kallio V, Puukka P. High fasting plasma insulin is an indicator of coronary heart disease in non-insulin-dependent diabetic patients and non-diabetic subjects. Arteriosclerosis 11: 80–90, 1991
Rosano GMC, Sarrel PM, Poole-Wilson PA, Collins P. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet 342: 133–136, 1993
Ross RK, Pike MC, Mack TM, Henderson BE. Oestrogen replacement therapy and cardiovascular disease. In Drife JO, Studd JWW (Eds) HRT and osteoporosis, pp. 209–222, Springer-Verlag, London, 1990
Scarabin P-Y, Bonithon-Kopp C, Bara L, Malmejac A, Guize L, et al. Factor VII activation and menopausal status. Thrombosis Research 57: 227–234, 1990
Sznajderman M, Oliver MF. Spontaneous premature menopause, is-chaemic heart disease and serum lipids. Lancet 1: 962–964, 1963
Spellacy WN, Buhi WC, Birk SA. The effects of estrogens on carbohydrate metabolism: glucose, insulin and growth hormone studies on one hundred and seventy one women ingesting Premarin, mestranol and ethinyl estradiol for six months. American Journal of Obstetrics and Gynecology 114: 378–392, 1972
Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 98: 83–90, 1993
Stevenson JC, Lees B, Bruce R, Ley C, Crook D. Influence of body composition on lipid metabolism in postmenopausal women. In Christiansen C, Overgaard K (Eds) Osteoporosis, pp. 1837–1838, Osteopress ApS, Copenhagen, 1990
Stout R. Insulin and atheroma: 20-yr perspective. Diabetes Care 13: 631–654, 1990
Swan J, Walton C, Godsland IF, Crook D, Oliver MF, et al. The insulin resistance syndrome as a feature of cardiological syndrome X in non-obese men. British Heart Journal, in press, 1994
Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout and uric calculus disease. American Journal of Clinical Nutrition 4: 20–34, 1956
Walton C, Godsland IF, Proudler AJ, Wynn V, Stevenson JC. The effects of the menopause on insulin sensitivity, secretion and elimination in non-obese, healthy women. European Journal of Clinical Investigation 23: 466–473, 1993
Williams JK, Adams MR, Klopfenstein HS. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation Research 81: 1680–1687, 1990
Winkler UH. Menopause, hormone replacement therapy and cardiovascular disease: a review of haemostaseological findings. Fibrinolysis 6 (Suppl. 3): 5–10, 1992
Winkler UH, Koslowski S, Oberhoff C, Schindler EM, Schindler AE. Changes of the dynamic equilibrium of hemostasis associated with the use of low dose oral contraceptives: a controlled study of Cyproteronacetate containing oral contraceptives combined with either 35 or 50μg ethinylestradiol. Advances in Contraception 7: 273–284, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stevenson, J.C., Crook, D., Godsland, I.F. et al. Hormone Replacement Therapy and the Cardiovascular System. Drugs 47 (Suppl 2), 35–41 (1994). https://doi.org/10.2165/00003495-199400472-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199400472-00007